Pharmaceutical firm Venus Remedies Ltd today said it has received Indian product patent for its antibiotic research product Vancoplus.
The Indian Patent Office (IPO) granted the licence which is valid till 2025, said Venus.
Vancoplus is a novel antibiotic entity that is highly effective against the notorious MRSA (methicillin—resistant staphylococcus aureus) bacterial strain and multi—drug resistant microbes primarily responsible for causing infections like meningitis, pneumonia, typhoid, septicaemia, urinary tract ailments and skin diseases, the company said.
“The research took more than seven years to develop this product. It is one of the best and safest options to get rid of drug—resistant gram—negative and gram—positive bacteria, MRSA, vancomycin—intermediate staphylococcus aureus (VISA) and heterogeneous glycopeptide—intermediate staphylococcus aureus (hGISA),” Venus Remedies Joint Managing Director Manu Chaudhary said in a statement here.
The total global market size of MRSA—associated infections is around $9 billion. At present, it is growing at 4.8 per cent, which is estimated to go up to 12.4 per cent by 2017. In India, Vancoplus is projected to cater to a market of Rs 214 crore by 2018—19.
So far, Venus has received patents for Vancoplus from more than 18 countries, including USA, Japan, South Africa, New Zealand, Ukraine and Australia. It is holding discussions with some multinational companies for the out-licensing of this product, the release added.